Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EPS (Weighted Average and Diluted) (2019 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.26 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 43.48% to -$0.26 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.13, a 105.7% increase, with the full-year FY2024 number at -$2.36, up 3.28% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.26 for Q3 2025 at Whitehawk Therapeutics, up from -$0.76 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $6.96 in Q4 2021 to a low of -$9.16 in Q3 2021.
  • A 5-year average of -$0.53 and a median of -$0.6 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 6381.04% in 2021, then skyrocketed 369.12% in 2025.
  • Whitehawk Therapeutics' EPS (Weighted Average and Diluted) stood at $6.96 in 2021, then plummeted by 106.9% to -$0.48 in 2022, then dropped by 25.0% to -$0.6 in 2023, then decreased by 13.33% to -$0.68 in 2024, then skyrocketed by 61.76% to -$0.26 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's EPS (Weighted Average and Diluted) are -$0.26 (Q3 2025), -$0.76 (Q2 2025), and $1.83 (Q1 2025).